GlassScriptPhysician profile
Kasim Qureshi
NPI 1538721543
$606.91
in general payments reported to CMS, 2019-2025
11 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $103 · 2023: $133 · 2024: $25.71 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $163.55 | 2023-2025 | |
| Aquestive Therapeutics, INC. | $124.99 | 2021 | |
| Genentech, INC. | $102.51 | 2022 | |
| Abbvie INC. | $78.80 | 2024-2025 | |
| Argenx US, INC. | $27.37 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Microtransponder, INC. | $22.99 | 2025 | |
| Biogen, INC. | $22.71 | 2025 | Vumerity, Tysabri |
| Pfizer INC. | $18.41 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $15.26 | 2025 | Austedo Xr |
| Celgene Corporation | $15.21 | 2025 | Zeposia |
| Abbott Laboratories | $15.11 | 2025 | Proclaim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasim Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.